Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoDTM Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

Authors

Jason Westin

Published

September 1, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Pathology And Forensic Medicine

DOI

10.1016/s2152-2650(24)00397-5

Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoDTM Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

Authors

Jason Westin

Published

September 1, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Pathology And Forensic Medicine

DOI

10.1016/s2152-2650(24)00397-5

Paper

Paper

Paper

Paper

Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoDTM Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

Abstract

Supporters

Journal

Topics

DOI

Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoDTM Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

Abstract

Supporters

Journal

Topics

DOI